HOUSE_OVERSIGHT_024897.jpg

2.09 MB
View Original

Extraction Summary

1
People
12
Organizations
4
Locations
4
Events
0
Relationships
3
Quotes

Document Information

Type: Market research report / financial analysis
File Size: 2.09 MB
Summary

This document is page 81 of a Cowen Collaborative Insights market research report dated February 25, 2019, discussing the regulatory landscape for medical cannabis and CBD in Europe, specifically the UK and Italy. It details the legalization history, licensing requirements involving agencies like the MHRA and FSA, and market activities of companies like GW Pharmaceuticals, Tilray, Bedrocan, Canopy, and Aurora. The document bears a 'HOUSE_OVERSIGHT_024897' Bates stamp, indicating it was part of a document production for a House Oversight Committee investigation.

People (1)

Name Role Context
Michael Cella Recipient
Listed in the sidebar watermark as the intended recipient of the report (michael.cella@cowen.com).

Timeline (4 events)

2013
Medical cannabis became legal in Italy.
Italy
2017
Military Chemical and Pharmaceutical Plant (MCPP) received license to cultivate medical cannabis.
Italy
MCPP
January 2019
UK Food Standards Agency (FSA) announced investigation of CBD products.
UK
FSA
November 2018
UK legalized prescription based medical cannabis.
UK

Locations (4)

Location Context
UK

Key Quotes (3)

"Despite changes in legality, the number of patients who have been prescribed medical cannabis treatments is quite limited."
Source
HOUSE_OVERSIGHT_024897.jpg
Quote #1
"Pure CBD is not a controlled substance under the Misuse of Drugs Act 1971."
Source
HOUSE_OVERSIGHT_024897.jpg
Quote #2
"This regulatory framework does not affect skincare, cosmetics or topicals with CBD or hemp ingredients."
Source
HOUSE_OVERSIGHT_024897.jpg
Quote #3

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein document